Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

NCT02162550 on ClinicalTrials.gov · last registry update 2018-06-14

148 participants. Its estimated completion date, April 2019, has passed with no update to the record. Primary outcome, as filed: Change in carotid plaque volume. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Phoenix VA Health Care System
Sponsor type: Fed
Enrollment: 148
Started: 2014-06
Primary completion: 2019-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in carotid plaque volume

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.